Tumor volumes in <scp>T3</scp> supraglottic cancers treated with radiotherapy in the modern era: A study of the Canadian Head & Neck Collaborative Research Initiative-Reference-Cited by-同舟云学术

Tumor volumes in T3 supraglottic cancers treated with radiotherapy in the modern era: A study of the Canadian Head & Neck Collaborative Research Initiative

Published:2023-12-20 Issue: Volume: Page:
ISSN:1043-3074
Container-title:Head & Neck
language:en
Short-container-title:Head & Neck

Author:

Malik Nauman H.¹²,Fu Rui³,Hainc Nicolin⁴⁵^ORCID,Noel Christopher W.³^ORCID,de Almeida John R.⁶,Hosni Ali²,Huang Shao Hui²,Yu Eugene⁵,Dzioba Agnieszka⁷,Leung Andrew⁸,Mangat Arvindpaul⁸,MacNeil Danielle⁷^ORCID,Nichols Anthony C.⁷^ORCID,Hiremath Shivaprakash B.⁹,Chakraborty Santanu⁹,Jooya Alborz¹⁰,Gaudet Marc¹⁰,Johnson‐Obaseki Stephanie¹¹,Whelan Jonathan¹¹,Forghani Reza¹²¹³,Hier Michael P.¹²,Morand Grégoire¹²^ORCID,Sultanem Khalil¹⁴,Dort Joseph¹⁵^ORCID,Lysack John¹⁶,Matthews Wayne¹⁵,Nakoneshny Steven¹⁵^ORCID,Gill Gia¹⁷,Globerman Adam¹⁸,Kerr Paul¹⁷,Maralani Pejman⁵,Karam Irene¹^ORCID,Eskander Antoine³

Affiliation:

1. Department of Radiation Oncology Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto Toronto Ontario Canada

2. Department of Radiation Oncology Princess Margaret Cancer Centre, University of Toronto Toronto Ontario Canada

3. Department of Otolaryngology–Head and Neck Surgery Sunnybrook Health Sciences Centre Toronto Ontario Canada

4. Department of Neuroradiology Clinical Neuroscience Center, University Hospital Zurich, University of Zurich Zurich Switzerland

5. Department of Medical Imaging University of Toronto Toronto Ontario Canada

6. Department of Otolaryngology‐Head and Neck Surgery Princess Margaret Cancer Centre—University Health Network, University of Toronto Toronto Ontario Canada

7. Department of Otolaryngology‐Head and Neck Surgery and Oncology London Health Sciences Center London Ontario Canada

8. Department of Radiology, Department of Medical Imaging Western University London Ontario Canada

9. Department of Radiology, Division of Neuroradiology University of Ottawa, The Ottawa Hospital Ottawa Ontario Canada

10. Division of Radiation Oncology The Ottawa Hospital, University of Ottawa Ottawa Ontario Canada

11. Department of Otolaryngology‐Head & Neck Surgery The Ottawa Hospital, University of Ottawa Ottawa Ontario Canada

12. Department of Otolaryngology Head and Neck Surgery McGill University, Jewish General Hospital Montreal Québec Canada

13. Department of Radiology University of Florida College of Medicine Gainesville Florida USA

14. Department of Oncology McGill University, Jewish General Hospital Montréal Québec Canada

15. Division of Otolaryngology‐Head and Neck Surgery University of Calgary Calgary Alberta Canada

16. Section of Neuroradiology, Department of Radiology Cumming School of Medicine, University of Calgary Calgary Alberta Canada

17. Department of Otolaryngology‐Head & Neck Surgery, Rady Faculty of Health Sciences University of Manitoba Winnipeg Manitoba Canada

18. Department of Radiology, Rady Faculty of Health Sciences University of Manitoba Winnipeg Manitoba Canada

Abstract

AbstractPurposeTo evaluate the association of primary tumor volume (TV) with overall survival (OS) and disease‐free survival (DFS) in T3 N0‐3M0 supraglottic cancers treated with intensity‐modulated radiotherapy (IMRT).MethodsThis was a retrospective cohort study involving 239 patients diagnosed with T3 N0‐3M0 supraglottic cancers between 2002 and 2018 from seven regional cancer centers in Canada. Clinical data were obtained from the patient records. Supraglottic TV was measured by neuroradiologists on diagnostic imaging. Kaplan–Meier method was used for survival probabilities, and a restricted cubic spline Cox proportional hazards regression analysis was used to analyze TV associations with OS and DFS.ResultsMean (SD) of participants was 65.2 (9.4) years; 176 (73.6%) participants were male. 90 (38%) were N0, and 151 (64%) received concurrent systemic therapy. Mean TV (SD) was 11.37 (12.11) cm3. With mean follow up (SD) of 3.28 (2.60) years, 2‐year OS was 72.7% (95% CI 66.9%–78.9%) and DFS was 53.6% (47.4%–60.6%). Increasing TV was associated (per cm3 increase) with worse OS (HR, 1.01, 95% CI 1.00–1.02, p < 0.01) and DFS (HR, 1.01, 95% CI 1.00–1.02, p = 0.02).ConclusionsIncreasing primary tumor volume is associated with worse OS and DFS in T3 supraglottic cancers treated with IMRT, with no clear threshold. The findings suggest that patients with larger tumors and poor baseline laryngeal function may benefit from upfront laryngectomy with adjuvant radiotherapy.

Publisher

Wiley

Subject

Otorhinolaryngology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hed.27608

Reference35 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Induction Chemotherapy plus Radiation Compared with Surgery plus Radiation in Patients with Advanced Laryngeal Cancer

3. Long-Term Results of RTOG 91-11: A Comparison of Three Nonsurgical Treatment Strategies to Preserve the Larynx in Patients With Locally Advanced Larynx Cancer

4. Laryngeal Cancer in the United States: Changes in Demographics, Patterns of Care, and Survival

5. Reexamining the treatment of advanced laryngeal cancer: The VA laryngeal cancer study revisited